, Volume 82, Issue 4, pp 310–317

The analysis and disposition of imipramine and its active metabolites in man

  • Tamara A. Sutfin
  • C. Lindsay DeVane
  • William J. Jusko
Original Investigations


Single oral and intramuscular (i.m.) doses of imipramine (IMI) were administered to four normal males. Serum and urine concentrations of IMI, desipramine (DMI) and their unconjugated 2-hydroxy metabolites were measured by high-pressure liquid chromatography (HPLC). Urinary conjugated 2-hydroxy metabolites were also measured after enzyme hydrolysis. Computer analysis of serum concentration and urinary excretion rate data allowed confirmation of drug and metabolite kinetics, and calculation of pharmacokinetic parameters. The rapid appearance of the metabolites in serum indicates that sequential firstpass metabolism of IMI involves both hydroxylation and demethylation. However, the dose-normalized areas under the serum concentration-time curves indicate that the fractions of the doses converted to metabolites were similar after both routes of IMI administration. Similar total fractions of the i.m. and oral doses recovered in urine indicate complete absorption of the oral doses. Inclusion of the metabolites increased the apparent availability of active components after oral IMI from 22%–50% to 45%–94%. Both the 2-hydroxy metabolites exhibited formation rate-limited kinetics, whereas DMI kinetics were elimination rate-limited. The t1/2 of IMI and 2-hydroxyimipramine (2-OH-IMI) was 6–18 h, while that of DMI and 2-hydroxydesipramine (2-OH-DMI) was 12–36 h. The t1/2 of these compounds was 1.5–2 times longer after the i.m. doses. The metabolite/parent ratios and the disposition of the individual metabolites confirm findings that chronic dosing results in only limited accumulation of hydroxy metabolites.

Key words

Imipramine Desipramine 2-Hydroxyimipramine 2-Hydroxydesipramine Active metabolites Metabolite disposition Pharmacokinetics First-pass metabolism Transit time Availability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bjerre M, Gram LF, Kragh-Sorensen P, Kristensen CB, Pedersen OL, Moller M, Thayssen P (1981) Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology 75:354–357Google Scholar
  2. Borga O, Piafsky KM, Nilsen OG (1977) Plasma protein binding of basic drugs I. Selective displacement from α1-acid glycoprotein by tris (2-butoxyethyl) phosphate. Clin Pharmacol Ther 22:539–544Google Scholar
  3. Brodie BB, Bickel MH, Sulser F (1961a) Desmethylimipramine, a new type of antidepressant drug. Med Exp 5:454–458Google Scholar
  4. Brodie B, Dick P, Kielholz P, Poldinger W, Theobald W (1961b) Preliminary pharmacological and clinical results with desmethylimipramine (DMI) 635020, a metabolite of imipramine. Psychopharmacologia 2:467–474Google Scholar
  5. DeVane CL, Jusko WJ (1981) Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine. Drug Intell Clin Pharmacol 15:263–266Google Scholar
  6. DeVane CL, Savett M, Jusko WJ (1981) Desipramine and 2-hedroxydesipramine pharmacokinetics in normal volunteers. Eur J Clin Pharmacol 19:61–64Google Scholar
  7. Gibaldi M, Perrier D (1975) Route of administration and drug disposition. In: Swarbrick J (ed) Pharmacokinetics. Marcel Dekker, New York; pp 229–252Google Scholar
  8. Gillette JR, Dingell JV, Sulser F, Kuntzman R, Brodie BB (1961) Isolation from rat brain of a metabolic product, desmethylimipramine, that mediates the antidepressant activity of imipramine (Tofranil). Experientia 17:417–418Google Scholar
  9. Gram LF, Christiansen J (1975) First-pass metabolism of imipramine in man. Clin Pharmacol Ther 17:555–563Google Scholar
  10. Gram LF, Fredricson-Overo K (1975) First-pass metabolism of nortriptyline in man. Clin Pharmacol Ther 18:305–314Google Scholar
  11. Gram LF, Andreasen PB, Overo KF, Christiansen J (1976) Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man. Psychopharmacology 50:21–27Google Scholar
  12. Heikkila RE, Goldfinger SS, Orlansky H (1976) The effect of various phenothiazines and tricyclic antidepressants on the accumulation and release of (3H) 5-hydroxytryptamine in slices of rat occipital cortex. Res Commun Chem Pathol Pharmacol 13:237–250Google Scholar
  13. Jandhyala BS, Steenberg ML, Rerel JM, Manian AA, Buckley JP (1977) Effects of several antidepressants on the hemodynamics and myocardial contractility of the anesthetized dogs. Eur J Pharmacol 42:403–410Google Scholar
  14. Lehman JP, Fenselau C, Depaulo JR (1983) Quaternary ammonium-linked glucuronides of amitriptyline, imipramine, and chlorpromazine. Drug Metab Dispos 11:221–225Google Scholar
  15. Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30:562Google Scholar
  16. Nagy A, Johansson R (1975) Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn-Schmiedeberg's Arch Pharmacol 290:145–160Google Scholar
  17. Nagy A, Johansson R (1977) The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology 54:125–131Google Scholar
  18. Nies AS, Shand DG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1:135–155Google Scholar
  19. Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK (1979) Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychol 14:601–613Google Scholar
  20. Potter WZ, Calil HM, Zavadil AP, Jusko WJ, Sutfin T, Rapoport JL, Goodwin FK (1980) Steady-state concentrations of hydroxylated metabolites of tricyclic antidepressants in patients: relationship to clinical effect. Psychopharmacol Bull 16:32–34Google Scholar
  21. Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK (1982) Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31:393–401Google Scholar
  22. Sutfin TA, Jusko WJ (1979) High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J. Pharmaceut Sci 68:703–705Google Scholar
  23. Veith RC, Raisys VA, Perera C (1978) The clinical impact of blood collection methods on tricyclic antidepressants as measured by GC/MS-SIM. Commun Psychopharmacol 2:491–494Google Scholar
  24. Walle T, Fagan TC, Conradi EC, Walle UK, Gaffney TE (1979) Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther 26:167–172Google Scholar
  25. Walle T, Conradi EC, Walle UK, Fagan TC, Gaffney TE (1980) 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther 27:22–31Google Scholar
  26. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547–558Google Scholar
  27. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6:79–97Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • Tamara A. Sutfin
    • 1
  • C. Lindsay DeVane
    • 1
    • 2
  • William J. Jusko
    • 1
  1. 1.Department of Pharmaceutics, School of PharmacyState University of New York at BuffaloBuffaloUSA
  2. 2.College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations